Merck & Co., Inc. (MRK)
Here is What to Know Beyond Why Merck & Co., Inc. (MRK) is a Trending Stock
Recently, Zacks.com users have been paying close attention to Merck (MRK). This makes it worthwhile to examine what the stock has in store.
Merck chicken bronchitis vaccine approved for use in China
Merck said its vaccine against bronchitis in chickens has been approved by the Chinese agriculture ministry for use in the world's largest chicken-rearing country, which is home to over 5 billion birds.
MRK Stock Gains After CHMP Backs Keytruda Combo for Bladder Cancer
Merck jumps after CHMP backs Keytruda plus Padcev for certain bladder cancer patients, a combo with the potential to expand treatment options.
Merck stock jumps as Keytruda combo trials boost cancer pipeline
Shares of Merck & Co. (MRK) rose 5% on Friday after the pharmaceutical giant reported positive developments across multiple oncology programs, reinforcing investor confidence in its efforts to extend the dominance of blockbuster cancer drug Keytruda ahead of looming patent expirations later this decade. The rally followed encouraging Phase 3 clinical trial results involving sacituzumab tirumotecan, or sac-TMT, an antibody-drug conjugate developed in partnership with Sichuan Kelun-Biotech Biopharmaceutical.
Will Weak Gardasil Sales Continue to Ail MRK's Vaccines Sales in 2026?
Merck's Gardasil sales plunge as weak China demand, inventory issues and softer Japan trends cloud the vaccine's overall growth outlook in 2026.
Kelun, Merck's lung cancer combo improves survival in late-stage China trial
Sichuan Kelun-Biotech Biopharmaceutical said on Thursday its experimental treatment combined with partner Merck's Keytruda improved survival rate in patients with advanced lung cancer, meeting the main goal of a late-stage study.
Regeneron Stock Sinks as Key Melanoma Drug Trial Fails to Beat Merck's Keytruda
A late-stage trial evaluating Regeneron's fianlimab, a skin cancer drug, fails to meet its primary endpoint.
Merck & Co., Inc. (MRK) is Attracting Investor Attention: Here is What You Should Know
Recently, Zacks.com users have been paying close attention to Merck (MRK). This makes it worthwhile to examine what the stock has in store.
Will Keytruda Continue to Aid MRK's Growth in 2026 After a Strong Q1?
Keytruda aids Merck's Q1 performance with $8B in sales. New indications plus combo therapies could fuel the drug's overall growth through 2026.
Merck Stock Down 7% in a Month: Should Investors Hold or Exit?
Merck falls 7% despite an earnings beat as a pipeline setback and Gardasil weakness act as dampeners. However, Keytruda and new launches support growth.
Merck (MRK) Price Forecast: Double Top Signals Deeper Correction Risk
Merck stock shows a confirmed double top breakdown, signaling potential downside risk, while key moving averages and resistance zones now shape the outlook for a deeper correction.
Merck: 'Strong Buy' - Terns Acquisition And Ability To Counter Keytruda Patent Loss
Merck retains a 'strong buy' rating, driven by proactive oncology pipeline expansion to offset KEYTRUDA patent expiration in 2028. Acquisition of Terns Pharmaceuticals brings TERN-701, a best-in-disease oral BCR-ABL1 TKI for CML, with multibillion-dollar potential and recent FDA Breakthrough Therapy Designation. The company advances the KEYTRUDA family with QLEX SC formulation and combination therapies, targeting new PDUFA approvals in bladder and renal cancers through 2026.
